The Effect of LDL557 on Improving Degenerative Arthritis in the Elderly

Sponsored by Chung Shan Medical University

About this trial

Last updated 8 months ago

Study ID

CS2-24147

Status

Enrolling by invitation

Type

Interventional

Phase

N/A

Placebo

Accepting

45 to 80 Years

All Sexes

Trial Timing

Started a year ago

What is this trial about?

This project is to conduct a clinical trial of SYNBIO TECH INC.'s LDL557 capsule for joint protection. To understand the improvement of joint discomfort and inflammation after supplementation, we hope to provide an updated choice for modern people's joint protection.

What are the participation requirements?

Inclusion Criteria

* BMI 18-40 kg/m2;

* Those with early stage degenerative arthritis symptoms judged by X-ray to be Kellgren-Lawrence Grading Scale level 1 or 2, and the physician determines that long-term treatment is not needed or WOMAC score>2.0 or WOMAC total scale score>12 or VAS score ≦6.

Exclusion Criteria

* Smoking

* alcoholism

* diabetes

* breastfeeding women and pregnant women.

* Those consuming dietary supplements were excluded.

* Those who use non-steroidal anti-inflammatory analgesics and those who have had joint surgery.

* Rheumatoid arthritis.

* Those who have had joint injections within 6 months.

* Those with cardiovascular and cerebrovascular, rheumatoid or mental diseases.

* Patients undergoing cancer treatment.